RJFSA
TXMD icon

Raymond James Financial Services Advisors’s TherapeuticsMD TXMD Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,559
Closed -$125K – 3426
2022
Q1 		$125K Sell
6,559
-118
-2% -$1.86K ﹤0.01% 3072
2021
Q4 		$119K Sell
6,677
-343
-5% -$10.3K ﹤0.01% 3096
2021
Q3 		$260K Buy
7,020
+325
+5% +$14.4K ﹤0.01% 2791
2021
Q2 		$398K Buy
6,695
+180
+3% +$10.9K ﹤0.01% 2530
2021
Q1 		$437K Sell
6,515
-59
-0.9% -$4.62K ﹤0.01% 2384
2020
Q4 		$398K Sell
6,574
-1,849
-22% -$126K ﹤0.01% 2282
2020
Q3 		$665K Buy
8,423
+432
+5% +$34.4K ﹤0.01% 1800
2020
Q2 		$499K Buy
+7,991
New +$465K ﹤0.01% 1926
2020
Q1 		– Sell
-7,327
Closed -$887K – 2835
2019
Q4 		$887K Sell
7,327
-590
-7% -$84.8K ﹤0.01% 1608
2019
Q3 		$1.44M Buy
7,917
+1,525
+24% +$215K 0.01% 1276
2019
Q2 		$831K Buy
6,392
+1,638
+34% +$294K ﹤0.01% 1602
2019
Q1 		$1.16M Buy
4,754
+228
+5% +$60.3K ﹤0.01% 1371
2018
Q4 		$862K Buy
4,526
+16
+0.4% +$3.9K ﹤0.01% 1342
2018
Q3 		$1.48M Buy
4,510
+240
+6% +$73.5K 0.01% 1231
2018
Q2 		$1.33M Buy
4,270
+669
+19% +$204K 0.01% 1248
2018
Q1 		$877K Buy
3,601
+74
+2% +$20.8K 0.01% 1384
2017
Q4 		$1.06M Buy
3,527
+668
+23% +$186K 0.01% 1259
2017
Q3 		$756K Buy
2,859
+601
+27% +$174K ﹤0.01% 1483
2017
Q2 		$595K Buy
2,258
+1,683
+293% +$422K ﹤0.01% 1582
2017
Q1 		$207K Buy
575
+207
+56% +$64.1K ﹤0.01% 2117
2016
Q4 		$106K Buy
+368
New +$114K ﹤0.01% 2184

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Raymond James Financial Services Advisors's TXMD Position: Q2 2022 in Review

Raymond James Financial Services Advisors sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 6,559 shares — an estimated $125K sold.

Raymond James Financial Services Advisors first reported a position in TXMD in Q4 2016 and held it in 21 quarters. The position peaked at $1.48M in Q3 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Raymond James Financial Services Advisors reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 6,559 TherapeuticsMD shares in Q2 2022, an estimated $125K.
  • Raymond James Financial Services Advisors first reported a position in TherapeuticsMD in Q4 2016 and held it in 21 quarters.
  • Raymond James Financial Services Advisors's TherapeuticsMD position peaked at $1.48M in Q3 2018.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.